Cited by 193Influenza Virus Research StudiesVirology and Viral DiseasesRNA Interference and Gene Delivery

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Self-replicating Semliki Forest virus RNA as recombinant vaccine

Zhou, X, Berglund, P, Rhodes, G, Parker, S.E, Jondal, M, Liljeström, P·1994·Vaccine

Open this paper in CoChat — free account

Abstract

Recombinant RNA based on the Semliki Forest virus (SFV) replicon was used to express the nucleoprotein of influenza virus in mice. Two strategies were employed to deliver the RNA. In the first, recombinant RNA was packaged into infectious suicide SFV particles which were used directly for immunization. The second approach involved injection of in vitro-synthesized RNA directly into the quadriceps muscle. Both approaches resulted in the generation of humoral responses with high antibody titres. Immunization with suicide particles showed that a strong, class I-restricted cytotoxic T-cell response can be obtained using only 100 infectious units. We conclude that the self-replicative recombinant SFV RNA may be quite useful as a nucleic acid vaccine.

Integrity signals

Registry

Crossref · 10.1016/0264-410x(94)90074-4

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Current protocols in molecular biology
Sargent, T. (1988) · Analytical Biochemistry · doi:10.1016/0003-2697(88)90147-9 · Cited by 7,281
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,659
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Self-citation
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides
Townsend, A. (1986) · Cell · doi:10.1016/0092-8674(86)90019-x · Cited by 1,711
Genetic immunization is a simple method for eliciting an immune response
Tang, D.-C. C., DeVit, M. J., & Johnston, S. A. (1992) · Nature · doi:10.1038/356152a0 · Cited by 1,504
MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
Germain, R. N. (1994) · Cell · doi:10.1016/0092-8674(94)90336-0 · Cited by 1,431
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.
Fynan, E. F., Webster, R. G., FULLER, D. H., Haynes, J. R., Santoro, J. C., & Robinson, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11478 · Cited by 1,116
The Biochemistry and Cell Biology of Antigen Processing and Presentation
Germain, R. N., & Margulies, D. H. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.002155 · Cited by 1,003
A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon
Liljeström, P., & Garoff, H. (1991) · Nature Biotechnology · doi:10.1038/nbt1291-1356 · Cited by 905
Self-citation
Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells
Rötzschke, O., Falk, K., Deres, K., Schild, H., Norda, M., Metzger, J. W., Jung, G., & Rammensee, H. (1990) · Nature · doi:10.1038/348252a0 · Cited by 771

Show all 32 references

Sorted by citations

mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 696
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507
Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses
Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501
Self-amplifying RNA vaccines for infectious diseases
Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487
Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genesin Vitroand Immunization against Heterologous Pathogensin Vivo
Pushko, P., Parker, M., Ludwig, G. V., Davis, N., Johnston, R. E., & Smith, J. (1997) · Virology · doi:10.1006/viro.1997.8878 · Cited by 444
DNA and RNA-based vaccines: principles, progress and prospects
Leitner, W. W., Han, Y., & Restifo, N. P. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00271-6 · Cited by 401
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways
Leitner, W. W., Hwang, L. N., DeVeer, M., Zhou, A., Silverman, R. H., Williams, B. R. G., Dubensky, T. W., Han, Y., & Restifo, N. P. (2002) · Nature Medicine · doi:10.1038/nm813 · Cited by 269
An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates
Erasmus, J. H., Khandhar, A. P., O’Connor, M. A., Walls, A. C., Hemann, E. A., Murapa, P., Archer, J., Leventhal, S., Fuller, J. T., Lewis, T. B., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9396 · Cited by 241
Self-citation
Alphavirus-based expression vectors: strategies and applications.
Frolov, I. V., Hoffman, T. A., Prágai, B. M., Dryga, S. A., Huang, H. V., Schlesinger, S., & Rice, C. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11371 · Cited by 238
Enhancing immune responses using suicidal DNA vaccines
Berglund, P., Smerdou, C., Fleeton, M. N., Tubulekas, L., & Liljeström, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0698-562 · Cited by 229
Self-citation
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., Solinís, M. Á., & del Pozo‐Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 229
Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines
Liljeqvist, S., & Ståhl, S. (1999) · Journal of Biotechnology · doi:10.1016/s0168-1656(99)00107-8 · Cited by 214
Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles
Davis, N., Caley, I. J., Brown, K. W., Betts, M. R., Irlbeck, D. M., McGrath, K. M., Connell, M. J., Montefiori, D. C., Frelinger, J. A., Swanstrom, R. I., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.1.371-378.2000 · Cited by 201
Current prospects for mRNA gene delivery
Yamamoto, A., Kormann, M., Rosenecker, J., & Rudolph, C. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.016 · Cited by 200
Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer
Dubensky, T. W., Driver, D. A., Polo, J. M., Belli, B., LATHAM, E. M., Ibañez, C. E., Chada, S., Brumm, D., Banks, T. A., Mento, S. J., et al. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.508-519.1996 · Cited by 192
RNA: The new revolution in nucleic acid vaccines
Geall, A. J., Mandl, C. W., & Ulmer, J. B. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.05.001 · Cited by 193
RNA-based vaccines
Ulmer, J. B., Mason, P. W., Geall, A. J., & Mandl, C. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.060 · Cited by 183
Self-Amplifying mRNA Vaccines
Brito, L. A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Scorza, F. B., Otten, G. R., Yu, D. L., Mandl, C. W., Mason, P. W., et al. (2014) · Advances in genetics · doi:10.1016/bs.adgen.2014.10.005 · Cited by 181
Alphavirus vectors and vaccination
Rayner, J. O., Dryga, S. A., & Kamrud, K. I. (2002) · Reviews in Medical Virology · doi:10.1002/rmv.360 · Cited by 181
DNA Immunization against Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector
Hariharan, M. J., Driver, D. A., Townsend, K., Brumm, D., Polo, J. M., Belli, B., Catton, D. J., Hsu, D. S., Mittelstaedt, D., McCormack, J. E., et al. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.950-958.1998 · Cited by 178
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus
Fleeton, M. N., Chen, M., Berglund, P., Rhodes, G., Parker, S. E., Murphy, M., Atkins, G. J., & Liljeström, P. (2001) · The Journal of Infectious Diseases · doi:10.1086/319857 · Cited by 157
Self-citation
Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
Cagigi, A., & Loré, K. (2021) · Vaccines · doi:10.3390/vaccines9010061 · Cited by 153
Messenger RNA-based vaccines
Pascolo, S. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.8.1285 · Cited by 152
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
Mossman, S. P., Bex, F., Berglund, P., Arthos, J. A., O'Neil, S. P., Riley, D. M., Maul, D. H., Bruck, C., Momin, P., Burny, A., et al. (1996) · Journal of Virology · doi:10.1128/jvi.70.3.1953-1960.1996 · Cited by 149
Self-citation
Encapsidation of the Flavivirus Kunjin Replicon RNA by Using a Complementation System Providing Kunjin Virus Structural Proteins in trans
Khromykh, A. A., Varnavski, A. N., & Westaway, E. G. (1998) · Journal of Virology · doi:10.1128/jvi.72.7.5967-5977.1998 · Cited by 142
Self-replicating alphavirus RNA vaccines
Ljungberg, K., & Liljeström, P. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.965690 · Cited by 141
Self-citation
Outcome of Immunization of Cynomolgus Monkeys with Recombinant Semliki Forest Virus Encoding Human Immunodeficiency Virus Type 1 Envelope Protein and Challenge with a High Dose of SHIV-4 Virus
Berglund, P., QUESADA-ROLANDER, M., Putkonen, P., Biberfeld, G., Thorstensson, R., & Liljeström, P. (1997) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1997.13.1487 · Cited by 135
Self-citation
DNA Vaccines: Technology and Application as Anti-parasite and Anti-microbial Agents
Alarcon, J. B., Waine, G. J., & McManus, D. P. (1999) · Advances in Parasitology/Advances in parasitology · doi:10.1016/s0065-308x(08)60152-9 · Cited by 130
Game changers in science and technology - now and beyond
Betz, U. A. K., Arora, L., Assal, R. A., de Azevedo, H. F. Z., Baldwin, J., Becker, M. S., Bostock, S., Cheng, V. W. T., Egle, T., Ferrari, N., et al. (2023) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2023.122588 · Cited by 153
In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model
Mandl, C. W., Aberle, J. H., Aberle, S. W., Holzmann, H., Allison, S. L., & Heinz, F. X. (1998) · Nature Medicine · doi:10.1038/4031 · Cited by 124
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector
Caley, I. J., Betts, M. R., Irlbeck, D. M., Davis, N., Swanstrom, R. I., Frelinger, J. A., & Johnston, R. E. (1997) · Journal of Virology · doi:10.1128/jvi.71.4.3031-3038.1997 · Cited by 122
A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs
Kallen, K., & Theß, A. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613508729 · Cited by 122
Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
Berglund, P., Fleeton, M. N., Smerdou, C., & Liljeström, P. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00224-2 · Cited by 117
Self-citation
Vaccines for Venezuelan equine encephalitis
Paessler, S., & Weaver, S. C. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.095 · Cited by 114
A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge
Davis, N., Brown, K. W., & Johnston, R. E. (1996) · Journal of Virology · doi:10.1128/jvi.70.6.3781-3787.1996 · Cited by 111
Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography
Asselin‐Paturel, C., Lassau, N., Jm, G., Zhang, J., Gay, F., Bex, F., Hallez, S., Leclère, J., PERONNEAU, P., Mami‐Chouaib, F., et al. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300841 · Cited by 107
Immune responses to DNA vaccines
Kowalczyk, D. W., & Ertl, H. C. J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050330 · Cited by 105
Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines
Vajdy, M., Srivastava, I. K., Polo, J., Donnelly, J., O’Hagan, D. T., & Singh, M. (2004) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2004.01288.x · Cited by 104
A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo
Johanning, F. W., Conry, R. M., LoBuglio, A. F., Wright, M., Sumerel, L. A., Pike, M. J., & Curiel, D. T. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.9.1495 · Cited by 99
Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses
Johansson, D. X., Ljungberg, K., Kakoulidou, M., & Liljeström, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029732 · Cited by 98
Self-citation
The molecular pathogenesis of Semliki Forest virus: a model virus made useful?
Atkins, G. J., Sheahan, B. J., & Liljeström, P. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-9-2287 · Cited by 98
Self-citation
A New Strategy in Design of (+)RNA Virus Infectious Clones Enabling Their Stable Propagation in E. coli
Yamshchikov, V. F., Mishin, V. P., & Cominelli, F. (2001) · Virology · doi:10.1006/viro.2000.0793 · Cited by 97
DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade
Giri, M. S., Ugen, K. E., & Weiner, D. B. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.370-389.2004 · Cited by 95
Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
Moyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.010 · Cited by 94
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96
Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections
Versteeg, L., Almutairi, M. M., Hotez, P. J., & Pollet, J. B. K. (2019) · Vaccines · doi:10.3390/vaccines7040122 · Cited by 94
Humoral and Cellular Immune Response to RNA Immunization with Flavivirus Replicons Derived from Tick-Borne Encephalitis Virus
Aberle, J. H., Aberle, S. W., Kofler, R. M., & Mandl, C. W. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15107-15113.2005 · Cited by 91
Alphavirus-Based Vaccines
Lundstrom, K. H. (2014) · Viruses · doi:10.3390/v6062392 · Cited by 91
Rise of the RNA machines – self-amplification in mRNA vaccine design
Comes, J. D. G., Pijlman, G. P., & Hick, T. A. H. (2023) · Trends in Biotechnology · doi:10.1016/j.tibtech.2023.05.007 · Cited by 87
A new generation of vaccines based on alphavirus self-amplifying RNA
Ballesteros-Briones, M. C., Silva-Pilipich, N., Herrador, G., Vanrell, L., & Smerdou, C. (2020) · Current Opinion in Virology · doi:10.1016/j.coviro.2020.08.003 · Cited by 89
Recombinant viruses as vaccines against viral diseases
de Souza, A. P. D., Haut, L. H., Reyes‐Sandoval, A., & Pinto, A. R. (2005) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2005000400004 · Cited by 87
Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine
Ward, G. B., Rieder, E. A., & Mason, P. W. (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7442-7447.1997 · Cited by 79
Current view on novel vaccine technologies to combat human infectious diseases
Matić, Z., & Šantak, M. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11713-0 · Cited by 83
mRNA vaccines: the most recent clinical applications of synthetic mRNA
Kwon, S., Kwon, M., Im, S., Lee, K., & Lee, H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01381-7 · Cited by 85
Self-Amplifying RNA Approach for Protein Replacement Therapy
Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76
Noncytopathic Flavivirus Replicon RNA-Based System for Expression and Delivery of Heterologous Genes
Varnavski, A. N., & Khromykh, A. A. (1999) · Virology · doi:10.1006/viro.1998.9564 · Cited by 74
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy
Caley, I. J., Betts, M. R., Davis, N., Swanstrom, R. I., Frelinger, J. A., & Johnston, R. E. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00142-5 · Cited by 70
Alphavirus vectors for vaccine production and gene therapy
Lundstrom, K. H. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.3.445 · Cited by 67
Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine
Fleeton, M. N., Sheahan, B. J., Atkins, G. J., & Liljeström, P. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-3-749 · Cited by 67
Self-citation
Alphavirus expression vectors and their use as recombinant vaccines: a minireview
Tubulekas, I., Berglund, P., Fleeton, M. N., & Liljeström, P. (1997) · Gene · doi:10.1016/s0378-1119(96)00679-8 · Cited by 67
Self-citation
Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.
Fleeton, M. N., Sheahan, B. J., Gould, E. A., Atkins, G. J., & Liljestrm, P. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-5-1189 · Cited by 64
Self-citation
Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems
Morris-Downes, M. M., Phenix, K. V., Smyth, J. A., Sheahan, B. J., Liljeqvist, S., MOONEY, D. A., Liljeström, P., Todd, D., & Atkins, G. J. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00428-x · Cited by 60
Self-citation
Comparative Analysis of Humoral Immune Responses to HIV Type 1 Envelope Glycoproteins in Mice Immunized with a DNA Vaccine, Recombinant Semliki Forest Virus RNA, or Recombinant Semliki Forest Virus Particles
Brand, D., Lemiale, F., Turbica, I., Buzelay, L., BRUNET, S., & Barin, F. (1998) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1998.14.1369 · Cited by 59
Type I Interferons are essential for the efficacy of replicase-based DNA vaccines
Leitner, W. W., Bergmann‐Leitner, E. S., Hwang, L. N., & Restifo, N. P. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.059 · Cited by 56
mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo
Cao, Q., Fang, H., & Tian, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122628 · Cited by 56
A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
Kimura, T., Leal, J. M., Simpson, A., Warner, N. L., Berube, B. J., Archer, J. F., Park, S., Kurtz, R., Hinkley, T., Nicholes, K., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.017 · Cited by 52
Self-citation
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 55
Self-citation
Modified mRNA as a Therapeutic Tool for the Heart
Kaur, K., & Zangi, L. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07051-4 · Cited by 50
Virus-based vectors for human vaccine applications
Polo, J. M., & Dubensky, T. W. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02324-3 · Cited by 48
Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein
Vignuzzi, M., Gerbaud, S., van der Werf, S., & Escriou, N. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-7-1737 · Cited by 47
Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action
Maruggi, G., Ulmer, J. B., Rappuoli, R., & Yu, D. L. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_233 · Cited by 46
Vaccines ‘on demand’: science fiction or a future reality
Ulmer, J. B., Mansoura, M. K., & Geall, A. J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.996128 · Cited by 45
Nucleic acid vaccines: research tool or commercial reality
Babiuk, L. A., Babiuk, S., Loehr, B. I., & den Hurk, S. V. D. L.-V. (2000) · Veterinary Immunology and Immunopathology · doi:10.1016/s0165-2427(00)00198-7 · Cited by 44
RNA Replicons - A New Approach for Influenza Virus Immunoprophylaxis
Zimmer, G. (2010) · Viruses · doi:10.3390/v2020413 · Cited by 43
Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens
Smith, M. L., Corbo, T. A., Bernales, J., Lindbo, J. A., Pogue, G. P., Palmer, K. E., & McCormick, A. A. (2006) · Virology · doi:10.1016/j.virol.2006.08.040 · Cited by 41
Delivery of synthetic mRNAs for tissue regeneration
Steinle, H., Weber, M., Stoppelkamp, S., Große‐Berkenbusch, K., Golombek, S., Weber, M., Çanak-Ipek, T., Trenz, S.-M., Schlensak, C., & Avci‐Adali, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114007 · Cited by 42
Alphaviruses as vectors for gene delivery
Berglund, P., Tubulekas, I., & Liljeström, P. (1996) · Trends in biotechnology · doi:10.1016/0167-7799(96)10019-6 · Cited by 41
Self-citation
The messenger's great message for vaccination
Pascolo, S. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1000871 · Cited by 40
In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future
Perenkov, A. D., Sergeeva, A. D., Vedunova, M. V., & Krysko, D. V. (2023) · Vaccines · doi:10.3390/vaccines11101600 · Cited by 40
Use of Conventional or Replicating Nucleic Acid-Based Vaccines and Recombinant Semliki Forest Virus-Derived Particles for the Induction of Immune Responses Against Hepatitis C Virus Core and E2 Antigens
Vidalin, O., Fournillier, A., Renard, N., Chen, M., Depla, E., Boucreux, D., Brinster, C., Baumert, T. F., Nakano, I., Fukuda, Y., et al. (2000) · Virology · doi:10.1006/viro.2000.0566 · Cited by 39
Self-citation
Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice
Cabrera, A. C., Sáez, D. R., Céspedes, S., Andrews, E. M., & Oñate, A. A. (2009) · Immunobiology · doi:10.1016/j.imbio.2008.11.016 · Cited by 38
The 'anti-hype' vaccine
DeFrancesco, L. (2017) · Nature Biotechnology · doi:10.1038/nbt.3812 · Cited by 40
Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA
Giraud, A., Ataman‐Önal, Y., Battail‐Poirot, N., Piga, N., Brand, D., Mandrand, B., & Verrier, B. (1999) · Journal of Virological Methods · doi:10.1016/s0166-0934(99)00009-9 · Cited by 36
Sindbis virus vectors for expression in animal cells
Huang, H. V. (1996) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(96)80057-7 · Cited by 36
Alphavirus Vectors: Applications for DNA Vaccine Production and Gene Expression
Lundstrom, K. H. (2000) · Intervirology · doi:10.1159/000053992 · Cited by 35
Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development
Phenix, K. V., Wark, K. L., Luke, C. J., Skinner, M. A., Smyth, J. A., Mawhinney, K. A., & Todd, D. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00026-3 · Cited by 34
Alphaviruses as expression vectors
Lundstrom, K. H. (1997) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(97)80032-8 · Cited by 32
Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform “Spotty Business”
Schoenly, K. A., & Weiner, D. B. (2007) · Journal of Virology · doi:10.1128/jvi.01634-07 · Cited by 32
Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives
Seregin, A. V., Nistler, R., Borisevich, V., Yamshchikov, G. V., Chaporgina, E., Kwok, C. W., & Yamshchikov, V. F. (2006) · Virology · doi:10.1016/j.virol.2006.07.038 · Cited by 31
Comparative Immunization Study Using RNA and DNA Constructs Encoding a Part of the Plasmodium falciparum Antigen Pf332
Andersson, C., Vasconcelos, N. ‐., Sievertzon, M., Haddad, D. E., Liljeqvist, S., Berglund, P., Liljeström, P., Ahlborg, N., Ståhl, S., & Berzins, K. (2001) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2001.00951.x · Cited by 30
Self-citation
A Semliki Forest virus replicon vectored DNA vaccine expressing the E2 glycoprotein of classical swine fever virus protects pigs from lethal challenge
Li, N., Qiu, H., Jian-jun, Z., Li, Y., Wang, M., Lu, B., Han, C.-G., Hou, Q., Wang, Z., Gao, H. J., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.08.020 · Cited by 30
Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primatesPreprint
Erasmus, J. H., Khandhar, A. P., Walls, A. C., Hemann, E. A., O’Connor, M. A., Murapa, P., Archer, J. F., Leventhal, S. S., Fuller, J., Lewis, T. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.28.121640 · Cited by 30
Self-citation
Delivery and Expression of Heterologous Genes in Mammalian Cells Using Self-Replicating Alphavirus Vectors
Karlsson, G. B., & Liljeström, P. (2004) · Humana Press eBooks · doi:10.1385/1-59259-650-9:543 · Cited by 29
Self-citation
Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses
Liu, Y., Li, Y., & Hu, Q. (2023) · Vaccines · doi:10.3390/vaccines11071142 · Cited by 27

Authors: Zhou, X., Berglund, P., Rhodes, G., Parker, S. E., Jondal, M., & Liljeström, P.
Affiliations: Karolinska Institutet (SE)
Vical (United States) (US)
Corresponding author: Liljeström, P
ORCID: Zhou, X
Berglund, P
Liljeström, P
Venue: Vaccine
Publisher: Elsevier BV
Published: 1994-12
Volume: 12
Issue: 16
Pages: 1510-1514
ISSN: 0264-410X (ISSN-L)
DOI: 10.1016/0264-410x(94)90074-4
OpenAlex: W2006168695
Cited by: 193
References: 32
Citations by year: 2026: 3 · 2025: 6 · 2024: 9 · 2023: 17 · 2022: 10 · 2021: 13 · 2020: 8 · 2019: 6 · 2018: 1 · 2017: 3 · 2015: 3 · 2014: 7 · 2013: 5 · 2012: 4
FWCI: 6.37
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Vaccine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: Semliki Forest virus, nucleic acid vaccines, influenza nucleoprotein, humoral immune response, cytotoxic T lymphocytes, self-replicating RNA
MeSH terms: Animals, Mice, Inbred BALB C, RNA, Viral, Semliki forest virus, T-Lymphocytes, Cytotoxic, Transfection, Vaccines, Synthetic, Viral Vaccines, Virus Replication, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Self-replicating Semliki Forest virus RNA as recombinant vaccine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks